상처 치료용 생물학적 제제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Wound Biologics Market Summary

The global wound biologics market size was valued at USD 2.6 billion in 2025 and is projected to grow from USD 2.8 billion in 2026 to USD 4.8 billion in 2033, at a CAGR of 8.1% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.5% in 2025. The wound biologics industry's growth is primarily driven by the rising prevalence of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers, coupled with the growing global burden of diabetes and an aging population.

Increasing demand for advanced regenerative therapies, continuous innovations in bioengineered skin substitutes and growth factor-based products, and expanding clinical adoption of biologic wound care solutions to accelerate healing and reduce complications are further supporting market growth.

The increasing prevalence of chronic wounds and diabetes is a major growth driver for the wound biologics market, as diabetic foot ulcers, venous leg ulcers, pressure ulcers, and other non-healing wounds require advanced therapies that promote tissue regeneration and accelerate healing. According to the International Diabetes Federation, diabetes cases continue to rise globally, increasing the number of patients at risk of chronic wound complications. Biologic wound care products, including skin substitutes, placental tissue allografts, and extracellular matrix (ECM)-based therapies, are being adopted to improve healing outcomes, reduce infection risk, and lower amputation rates in patients with complex wounds.

The growing number of surgical procedures and traumatic injuries is a key driver of the wound biologics market, as these conditions often require advanced wound management to accelerate tissue regeneration and reduce the risk of complications, such as infection and delayed healing. Biologic wound care products, including skin substitutes, amniotic membrane allografts, and extracellular matrix (ECM)-based therapies, are increasingly being used in complex surgical wounds, orthopedic procedures, burns, and trauma cases. The rising global surgical volume and increasing incidence of road traffic accidents, sports injuries, and burn injuries continue to expand the demand for regenerative wound biologics across hospitals and trauma centers.

Global Wound Biologics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global wound biologics market report based on product, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biological Skin Substitutes
  • Allograft
  • Xenograft
  • Biosynthetic Products
• Topical Agents
• Collagen Dressing
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Chronic Wounds
• Acute Wounds
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Product
  • 1.1.2. Wound Type
  • 1.1.3. End Use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Wound Biologics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising prevalence of chronic wounds and diabetes
    • 3.2.1.2. Increasing number of surgical procedures and traumatic injuries
    • 3.2.1.3. Rising adoption of regenerative medicine and advanced wound care therapies
    • 3.2.1.4. Growing clinical evidence supporting biologic skin substitutes
    • 3.2.1.5. Increasing incidence of burns and pressure ulcers
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of biologic wound care products
    • 3.2.2.2. Limited reimbursement coverage across several countries
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Expansion of regenerative medicine and tissue engineering
    • 3.2.3.2. Development of next-generation bioengineered skin substitutes
    • 3.2.3.3. Growing adoption of placental tissue and extracellular matrix (ECM)-based products
    • 3.2.3.4. Increasing integration of ai and digital wound assessment with biologic therapies
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Stringent regulatory and clinical evidence requirements
    • 3.2.4.2. Pricing pressure and healthcare cost containment measures
• 3.3. Wound Biologics Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Wound Biologics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Wound Biologics Market: Product Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Global Wound Biologics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Biological Skin Substitutes
  • 4.4.1. Biological skin substitutes market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Allograft
    • 4.4.2.1. Allograft market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Xenograft
    • 4.4.3.1. Xenograft market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Biosynthetic Products
    • 4.4.4.1. Biosynthetic products market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Topical Agents
  • 4.5.1. Topical agents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Collagen Dressing
  • 4.6.1. Collagen dressing market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Wound Biologics Market: Wound Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Wound Biologics Market: Wound Type Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Global Wound Biologics Market Size & Trend Analysis, by Wound Type 2021 to 2033 (USD Million)
• 5.4. Chronic Wounds
  • 5.4.1. Chronic wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Acute Wounds
  • 5.5.1. Acute Wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Wound Biologics Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Wound Biologics Market: End use Movement Analysis, 2025 & 2033 (USD Million)
• 6.3. Global Wound Biologics Market Size & Trend Analysis, by End use 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Specialty Clinics
  • 6.5.1. Specialty Clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Ambulatory Surgical Centers
  • 6.6.1. Ambulatory surgical centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Wound Biologics Market: Regional Estimates & Trend Analysis by Product, Wound Type and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. Reimbursement scenario
    • 7.3.2.5. U.S. wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Reimbursement scenario
    • 7.3.3.5. Canada wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Reimbursement scenario
    • 7.3.4.5. Mexico wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Reimbursement scenario
    • 7.4.2.5. UK wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Reimbursement scenario
    • 7.4.3.5. Germany wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Reimbursement scenario
    • 7.4.4.5. France wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Reimbursement scenario
    • 7.4.5.5. Italy wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Reimbursement scenario
    • 7.4.6.5. Spain wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Reimbursement scenario
    • 7.4.7.5. Sweden wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Reimbursement scenario
    • 7.4.8.5. Denmark wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Reimbursement scenario
    • 7.4.9.5. Norway wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. China wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Japan
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Japan wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. India wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Reimbursement scenario
    • 7.5.5.5. South Korea wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Reimbursement scenario
    • 7.5.6.5. Australia wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. Thailand wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Brazil wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Argentina wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Middle East and Africa
  • 7.7.1. Middle East and Africa wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. South Africa wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. Saudi Arabia wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. UAE wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Kuwait wound biologics market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Market Share Analysis, 2025
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Product Launches
  • 8.5.5. Research And Development
  • 8.5.6. Company Profiles
  • 8.5.7. MIMEDX Group, Inc
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Integra LifeSciences Corporation
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Organogenesis Inc.
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. BioTissue
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. Skye Biologics Holdings, LLC
    • 8.5.11.1. Company overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. Tissue Regenix Group
    • 8.5.12.1. Company overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic initiatives
  • 8.5.13. Vericel Corporation
    • 8.5.13.1. Company overview
    • 8.5.13.2. Financial performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic initiatives
  • 8.5.14. Stimlabs LLC
    • 8.5.14.1. Company overview
    • 8.5.14.2. Financial performance
    • 8.5.14.3. Product Benchmarking
    • 8.5.14.4. Strategic initiatives
  • 8.5.15. Tides Medical
    • 8.5.15.1. Company overview
    • 8.5.15.2. Financial performance
    • 8.5.15.3. Product Benchmarking
    • 8.5.15.4. Strategic initiatives
  • 8.5.16. AlloSource
    • 8.5.16.1. Company overview
    • 8.5.16.2. Financial performance
    • 8.5.16.3. Product Benchmarking
    • 8.5.16.4. Strategic initiatives
  • 8.5.17. LifeNet Health
    • 8.5.17.1. Company overview
    • 8.5.17.2. Financial performance
    • 8.5.17.3. Product Benchmarking
    • 8.5.17.4. Strategic initiatives
  • 8.5.18. MTF Biologics
    • 8.5.18.1. Company overview
    • 8.5.18.2. Financial performance
    • 8.5.18.3. Product Benchmarking
    • 8.5.18.4. Strategic initiatives
  • 8.5.19. Stryker
    • 8.5.19.1. Company overview
    • 8.5.19.2. Financial performance
    • 8.5.19.3. Product Benchmarking
    • 8.5.19.4. Strategic initiatives
  • 8.5.20. Convatec
    • 8.5.20.1. Company overview
    • 8.5.20.2. Financial performance
    • 8.5.20.3. Product Benchmarking
    • 8.5.20.4. Strategic initiatives
  • 8.5.21. Smith+Nephew
    • 8.5.21.1. Company overview
    • 8.5.21.2. Financial performance
    • 8.5.21.3. Product Benchmarking
    • 8.5.21.4. Strategic initiatives